Neil K. Warma

CIK: 0001437911

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PMN

ProMIS Neurosciences Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

PMN
ProMIS Neurosciences Inc.
May 20, 2026
Award(A)
Option (right to buy)
Direct
160K shares-
PMN
ProMIS Neurosciences Inc.
Feb 3, 2026
Award(A)
Direct
6.2K shares at avg. $12.13$75K
PMN
ProMIS Neurosciences Inc.
Sep 22, 2025
Award(A)
Option (right to buy)
Direct
600K shares-
PMN
ProMIS Neurosciences Inc.
Oct 8, 2024
Award(A)
Option (right to buy)
Direct
1.1M shares-
PMN
ProMIS Neurosciences Inc.
Oct 8, 2024
Award(A)
Option (right to buy)
Direct
490.3K shares-

		Type	Shares	Price		Ownership
May 20, 2026	PMN ProMIS Neurosciences Inc.	Award(A) Option (right to buy)	160,000	-	-	Direct
Feb 3, 2026	PMN ProMIS Neurosciences Inc.	Award(A)	6,183	$12.13	$75,000	Direct
Sep 22, 2025	PMN ProMIS Neurosciences Inc.	Award(A) Option (right to buy)	600,000	-	-	Direct
Oct 8, 2024	PMN ProMIS Neurosciences Inc.	Award(A) Option (right to buy)	1,144,122	-	-	Direct
Oct 8, 2024	PMN ProMIS Neurosciences Inc.	Award(A) Option (right to buy)	490,338	-	-	Direct

1-5 of 5 transactions

About Warma Neil K

Warma Neil K (SEC CIK 0001437911) files insider reports with the SEC as Chief Executive Officer of ProMIS Neurosciences Inc. (PMN).

Signal8 holds 4 ownership filings by Warma Neil K, all Form 4s, filed between Oct 10, 2024 and May 22, 2026. Those filings report 5 transactions, from Oct 8, 2024 to May 20, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Warma Neil K's filings is in TORONTO, A6.

Recent filings by Warma Neil K

May 20, 2026: Grant or award of PMN derivative securities (Form 4, code A).
Feb 3, 2026: Grant or award of PMN shares (Form 4, code A).
Sep 22, 2025: Grant or award of PMN derivative securities (Form 4, code A).
Oct 8, 2024: Grants or awards of PMN derivative securities (2 lines, Form 4, code A).

Other insiders filing for ProMIS Neurosciences Inc. (PMN)

Williams Eugene, Director
Cashman Neil, Chief Scientific Officer
Rubino Ivana, Chief Commercial Officer
Kaplan Johanne, Chief Development Officer
WYMAN WILLIAM W, Director
Shafmaster Madge K., Director

How to read Form 4 transaction codes